New Book Offers a Breakthrough Framework for De-Risking Medical Technology Investments

​

Miami, FL - [March 1, 2026] - When evaluating the social benefits of medical innovation through the aggregate improvements in human longevity, Murphy and Topel attributed a value of roughly US$57 trillion (or about US$2.8 trillion per year) to the increased life expectancy of Americans over the period 1970–1990. But with medical technology startups still showing failure rates above 75%, this critical social value keeps being highly constrained. Not surprisingly, at the end of 2025, PitchBook Data shows that the number of currently disclosed VC transactions in medical technology represents the lowest quarterly deal count since at least 2018. A trend characterized by fewer, larger rounds that increasingly favor top-tier companies, leaving the majority of medical startups fighting for a smaller pool of capital. 

​

In this context, a new book by global medtech strategist Luigi Negri aims to equip investors, founders, and industry leaders with a practical roadmap to navigate risk and unlock opportunity in the fast-moving world of medical technology.

Published by Springer, De-Risking Investments in Medical Technology Innovation: Strengthening Decision-Making and Valuation Accuracy in Medical Startups provides a comprehensive, evidence-based system for evaluating early-stage ventures and improving the quality of decisions that ultimately make or break value creation.

​

A Practical Guide for a Complex, High-Stakes Sector

“Medical technology has never been more essential, or more complex. Over the past two decades, global medical knowledge has accelerated at an exponential rate, while entrepreneurs must manage a widening web of stakeholders, regulatory pressures, cross-disciplinary science, and commercialization hurdles,” author Luigi Negri notes. “These challenges have kept many investors on the sidelines, depriving the sector of critical capital.”

 

Negri’s book introduces a structured approach to overcoming these barriers. Readers will find a science-based decision-making methodology that maximizes their chances of success. The reader is left with a set of valuable, practical tools that can be applied individually and concurrently:

​

• A valuation approach that moves the focus from the sophistication of the forecasting and financial methodologies to the quantitative importance of high-quality business assumptions.

• A complete set of mental maps organized and compellingly tailored to the business of medical technology innovation; maps that visualize and mutually link the medical venture’s prediction problems and the venture’s predicted value. 

• Real-life examples of how the scientific approach to decision-making can be used in medical technology startups outside the clinical trial area. 

 

The goal of the book is to reduce uncertainty, elevate judgment, and open the door to more confident investment in life-changing technologies.

​

ABOUT THE AUTHOR

Luigi Negri is the Managing Partner at Thinkeen® Global Consulting and Partner at Obloo Ventures, where he specializes in the valuation, strategy, and commercialization of medical technology startups worldwide. Since founding Thinkeen in 2013, he has advised founders and industry leaders across the life sciences ecosystem.

His career spans senior general management and commercial roles across global corporations, including CR Bard, Baxter, and LivaNova, with leadership responsibilities across Europe, Russia, Latin America, and emerging markets. Negri has received multiple corporate awards for global and European excellence and has been featured in Forbes for his commercial performance. He is currently a member of the Forbes Council in the United States.

More at: https://luiginegri.com

De-Risking Investments in Medical Technology Innovation is now available through Springer: https://link.springer.com/book/9783032150066#affiliations